Nasal Drops Restore Memory in Mice, Study Finds

The treatment, tested on mice only, uses the same mRNA technology made famous by coronavirus vaccines — but this time the instructions it carries tell nasal cells to make a brain-protecting protein rather than a viral one.

Nasal drops that tell nose cells to make a brain-protecting protein restored memory in aged mice, in what researchers call a potential first non-surgical route into the brain.

The findings were reported on Wednesday and Thursday this week by outlets including Al-Arabiya, Shafaq News and Al-Khaleej. The treatment sidesteps the blood-brain barrier, the protective membrane that blocks most drugs from reaching brain tissue.

How the Drops Work

The team packaged messenger RNA inside tiny fatty nanoparticles and delivered it to mice as simple nasal drops. The mRNA instructs cells in the nasal cavity to produce brain-derived neurotrophic factor, or BDNF, a protein essential for keeping nerve cells alive, forming memories and maintaining the connections between them, according to Al-Ayam’s report. Levels of the protein fall with age, and low levels are linked to Alzheimer’s disease.

Giving BDNF directly through the nose has long failed because the protein breaks down quickly in the nasal lining, limiting how much reaches the brain. By making the cells produce the protein themselves, the researchers got around that problem. Lab tests showed the protein kept being produced for up to four days after a single dose, Al-Arabiya reported.

Nasal Drops Restore Memory in Mice, Study Finds
Photo: شفق نيوز

The technique is the same one used in some coronavirus vaccines, which trained the immune system on a harmless piece of the virus. Here, the instructions were aimed at a protein that supports nerve cells instead, Al-Weeam noted.

Memory in Aged Mice Returns to Youthful Levels

In the first experiment, 18-month-old mice — old by mouse standards — received the drops and showed marked improvement in learning and memory tests. Their cognitive performance approached that of young mice. Brain examinations found a 2.4-fold increase in cells expressing doublecortin, a marker of new neuron formation, compared with control groups, Al-Araby reported.

The team then tested the treatment on genetically modified mice known as the 5XFAD model, which carry mutations producing brain changes resembling some features of Alzheimer’s in humans. In these animals, disease deposits normally begin around two months of age, with clear cognitive decline appearing near four months, Al-Ayam reported.

Researchers tested the model with the treatment, and tests showed improved memory and increased new neurons in the hippocampus. Amyloid deposits did not decrease, the report said.

Memory Improved Without Touching Amyloid

The most striking result, several outlets agree, is what did not change. The treatment did not reduce amyloid plaques, the protein buildups associated with Alzheimer’s. That sets this approach apart from current drugs that target amyloid removal from the brain, and it opens the possibility of using both approaches together in the future, Al-Ayam reported.

Nasal Drops Restore Memory in Mice, Study Finds
Photo: صحيفة الوئام

The researchers argue that keeping nerve cells healthy, alive and communicating may protect cognitive function even where disease-related changes exist. Improved memory alongside unchanged plaques, they suggest, could help brain function even in patients who have already lost some nerve cells — making the approach a complement to other treatments rather than a replacement, Al-Ma’louma reported.

The team also sees the platform extending beyond BDNF. Success could open the door to boosting other nerve-supporting proteins, including NGF and GDNF, Shafaq News reported.

Human Trials Targeted Within Two Years

The technique has so far been tested only in mice, and has not been shown to be effective or safe in humans. The researchers hope to complete the required safety tests in animals and begin human trials within two years, if safety results and regulatory approvals allow, Al-Ayam reported.

The team plans additional animal safety studies as a step toward clinical trials in humans within the next two years. The work could eventually add a non-surgical option to current efforts against dementia and Alzheimer’s, Al-Araby reported.

Photo of author

Newsroom

Newsroom at Archyde.

Indonesia Shuts 14 Rural Banks in 2026, LPS Blames Weak Governance